Miniatura

Fitxers

Final analysis of the phase III non-inferiority COLUMBA_Haematologica.pdf (5.4 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-10

Llicència de publicació

cc by-nc (c) Usmani, Saad Z. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/202060

Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3324/haematol.2021.279459

Resum

In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demon-strated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the final analysis of efficacy and safety from COLUMBA after a median of 29.3 months follow-up (additional 21.8 months after the primary analysis). In total, 522 patients were randomized (DARA SC, n=263; DARA IV, n=259). With longer follow-up, DARA SC and DARA IV continued to show consistent efficacy and maximum trough daratumumab concentration as compared with the primary analysis. The overall response rate was 43.7% for DARA SC and 39.8% for DARA IV. The maxi-mum mean (standard deviation [SD]) trough concentration (cycle 3, day 1 pre-dose) of serum DARA was 581 (SD, 315) mu g/mL for DARA SC and 496 (SD, 231) mu g/mL for DARA IV. Median progression-free survival was 5.6 months for DARA SC and 6.1 months for DARA IV; median overall survival was 28.2 months and 25.6 months, respectively. Grade 3/4 treatment-emergent adverse events occurred in 50.8% of patients in the DARA SC group and 52.7% in the DARA IV group; the most common (>= 10%) were thrombocytopenia (DARA SC, 14.2%; DARA IV, 13.6%), anemia (13.8%; 15.1%), and neutropenia (13.1%; 7.8%). The safety profile remained consistent with the primary analysis after longer follow-up. In summary, DARA SC and DARA IV continue to demonstrate similar efficacy and safety, with a low rate of infusion-related reactions (12.7% vs. 34.5%, respectively) and shorter administration time (3-5 minutes vs. 3-7 hours) supporting DARA SC as a preferable therapeutic choice. (Clinicaltrials gov. Identifier: NCT03277105.

Matèries

Administració de medicaments, Mieloma múltiple, Anticossos monoclonals

Matèries (anglès)

Administration of drugs, Multiple myeloma, Monoclonal antibodies

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

USMANI, Saad z., NAHI, Hareth, LEGIEC, Wojciech, GROSICKI, Sebastian, VOROBYEV, Vladimir, SPICKA, Ivan, HUNGRIA, Vania, KORENKOVA, Sibirina, BAHLIS, Nizar j., FLOGEGARD, Max, BLADÉ, J. (joan), MOREAU, Philippe, KAISER, Martin, IIDA, Shinsuke, LAUBACH, Jacob, MAGEN, Hila, CAVO, Michele, HULIN, Cyrille, WHITE, Darrell, STEFANO, Valerio de, LANTZ, Kristen, O'ROURKE, Lisa, HEUCK, Christoph, DELIOUKINA, Maria, QIN, Xiang, NNANE, Ivo, QI, Ming, MATEOS, María victoria. Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. _Haematologica_. 2022. Vol. 107, núm. 10, pàgs. 2408-2417. [consulta: 5 de febrer de 2026]. ISSN: 1592-8721. [Disponible a: https://hdl.handle.net/2445/202060]

Exportar metadades

JSON - METS

Compartir registre